The global virtual clinical trials market was valued at USD 8.75 billion in 2023, and it is projected to expand at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2030. This growth is primarily attributed to the increase in research and development (R&D) activities, the digitization of the healthcare industry, and the widespread adoption of telehealth solutions. Furthermore, the market is being propelled by rapid technological advancements, growing collaborations between clinical research organizations (CROs), pharmaceutical firms, and biotechnology companies, as well as supportive regulatory and governmental initiatives. The COVID-19 pandemic served as a major inflection point for the industry, as it necessitated a shift from traditional, site-based clinical trials to more flexible, remote, and technology-enabled trial models, thereby accelerating the adoption of virtual clinical trials.

The increasing integration of digital technologies into healthcare systems is expected to further fuel market expansion. Digital transformation is revolutionizing the drug development landscape, with the introduction of tools such as mobile apps, wearable devices, artificial intelligence (AI), cloud computing, and digital health platforms. These technologies facilitate the continuous, precise, and multidimensional collection of clinical data, enhancing trial design, execution, and monitoring throughout the entire study period. They allow for the creation of innovative and adaptive trial frameworks that not only streamline participant recruitment and retention but also improve patient engagement, compliance, and the identification of novel clinical endpoints.

A pivotal development in the virtual trial model is the adoption of patient-centric strategies. This approach places participants at the center of the clinical trial process to improve experience and outcomes. Leading pharmaceutical companies, such as Pfizer and Sanofi, have restructured their clinical development strategies to align with this model. They have introduced smartphone applications and wearable health monitoring devices to enhance data acquisition and facilitate real-time communication with trial participants. These technologies provide researchers with access to behavioral and health data collected in real-world settings, offering a more holistic understanding of treatment efficacy and safety.

The virtual model allows participants to enroll and engage in clinical studies from the comfort of their homes, ensuring that trials can proceed even in circumstances that restrict in-person site visits. This not only improves participant safety by minimizing exposure to potential health risks but also offers greater flexibility and convenience, thereby enhancing overall satisfaction and participation rates. Virtual clinical trials also support remote patient monitoring and telemedicine visits, giving participants a sense of control while maintaining consistent data collection standards.

Additionally, by removing geographical barriers, virtual clinical trials enable sponsors to reach and recruit a more diverse and extensive patient population, which significantly enhances study inclusivity and representativeness. Continuous and real-time data collection through integrated digital health systems improves data accuracy, timeliness, and regulatory compliance. The use of virtual platforms for trial management also helps reduce the burden on participants, clinical research coordinators (CRCs), and investigators, leading to more efficient study execution with lower time and resource investment.

In summary, the virtual clinical trials market is undergoing transformative growth, supported by technological innovation, evolving patient expectations, and a fundamental shift in how clinical research is conducted and managed. As this model continues to evolve, it is expected to play a vital role in shaping the future of clinical development worldwide.

Get a preview of the latest developments in the Virtual Clinical Trials Market? Download your FREE sample PDF copy today and explore key data and trends

Detailed Segmentation:

Study Design Insights

Interventional design segment led the virtual clinical trials market with largest revenue share of 46.8% in 2023. The rapid increase in number of experiments to develop novel medications for various diseases and the digitalization of laboratories are factors driving the segment. 

Indication Insights

Oncology segment dominated a market for virtual/decentralized clinical trials and accounted for a largest revenue share of over 25.0% in 2023. The segment is also anticipated to contribute to the maximum share of a market during the forecast period. 

Phase Insights

Phase II segment dominated virtual clinical trials market and accounted for largest revenue share of over 30% in 2023. This is largely due to the adoption of DCT tools and platforms in phase II and phase I clinical trial procedures for patient participation. 

Regional Insights

North America accounted for a largest regional revenue share of 48.73% in 2023 and is expected to continue its dominance over the forecast period. This can be attributed to increasing R&D in this region, increasing an adoption of new technologies in clinical research as well as government support. Furthermore, market players are also using digital technologies to meet client needs. 

Key Virtual Clinical Trials Companies:

The following are the leading companies in the virtual clinical trials market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps & products of these virtual clinical trials companies are analyzed to map the supply network.

• ICON, plc
• Parexel International Corporation
• IQVIA
• Covance
• PRA Health Sciences
• LEO Innovation Lab
• Medidata
• Oracle
• CRF Health
• Clinical Ink
• Medable, Inc.
• Signant Health
• Halo Health Systems
• Croprime

Recent Developments

• In July 2023, Signant Health completed the acquisition of DSG, strategically augmenting its eClinical solution suite for both traditional and decentralized clinical trials. By integrating DSG's unified platform, the acquisition facilitated the development of a comprehensive trial ecosystem equipped with advanced software, analytics, and logistics solutions, enabling seamless study conduct and data generation across all modalities, thereby accomplishing the goal of fully digitalizing clinical trials.
• In June 2023, Medable Inc. unveiled a comprehensive toolkit tailored for Institutional Review Boards (IRBs)/Ethics Committees (ECs), designed to establish standardized ethics review procedures for decentralized clinical trials (DCTs). The implementation of this toolkit successfully simplified, streamlined, and accelerated the IRB/EC process, playing a pivotal role in fostering enhanced efficiency and patient-centeredness in the execution of DCTs.
• In October 2022, Oracle and ObvioHealth entered into a strategic collaboration to integrate diverse data sets into virtual/decentralized clinical trials in the Asia Pacific region. This initiative is expected to allow the quick collection, integration and analysis of multi-source data collected from labs, devices, patients, and sites.

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.